Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 655,000	$ 655,000
Accounts receivable, net of allowance	355,000	257,000
Inventories, net of allowance	16,000	26,000
Prepaid expenses and other current assets	39,000	17,000
Total current assets	1,065,000	955,000
In-process research and development (Note 9)	1,893,000	1,893,000
Equipment, net of depreciation	95,000	126,000
Other non-current assets	35,000	35,000
Right of use, operating lease, net of amortization	411,000
Deferred offering cost	122,000	176,000
Total assets	3,621,000	3,185,000
Current liabilities:
Accounts payable and accrued expenses	602,000	501,000
Note payable	50,000	400,000
Line of credit	50,000	430,000
Convertible notes payable	3,957,000	1,365,000
Discount on convertible notes payable, and line of credit, net of amortization	(1,472,000)	(205,000)
Deferred revenue	35,000
Lease liability, current	125,000
Total current liabilities	4,354,000	2,491,000
Long-term liabilities:
Long-term debt	700,000	1,292,000
Discount on convertible notes payable, net of amortization	(182,000)	(118,000)
Lease liability	286,000
Total liabilities	5,801,000	4,308,000
COMMITMENTS, CONTINGENCIES (Note 12)
STOCKHOLDERS’ EQUITY (DEFICIT):
Preferred Series A, $.00067 Par Value, 50,000,000 Shares Authorized, -0- Shares Issued and Outstanding, at December 31, 2018 and December 31, 2019, respectively.
Common stock, $.00067 Par Value, 400,000,000 Shares Authorized, 141,466,071 and 166,256,024 Shares Issued, at December 31, 2018 and December 31, 2019, respectively.	111,000	95,000
Additional paid-in capital	121,327,000	110,222,000
Accumulated other comprehensive loss	(99,000)	(90,000)
Accumulated deficit	(123,492,000)	(111,723,000)
Total Biolargo Inc. and Subsidiaries stockholders’ equity (deficit)	(2,153,000)	(1,496,000)
Non-controlling interest (Note 9)	(27,000)	373,000
Total stockholders’ equity (deficit)	(2,180,000)	(1,123,000)
Total liabilities and stockholders’ equity (deficit)	3,621,000	3,185,000
Scion Acquisition [Member] | Clyra Acquisition, Common Stock Redeemable for BioLargo Common Shares [Member]
Long-term liabilities:
Liability to Clyra Medical shareholder (Note 9)	643,000	643,000
Convertible Notes Issued by Clyra Medical Maturing on June 17, 2020 [Member]
Current liabilities:
Note payable	1,007,000
Long-term liabilities:
Long-term debt		1,007,000
Convertible Notes and Notes Payable [Member]
Long-term liabilities:
Long-term debt	$ 700,000	$ 285,000